Article

Allergy drug efficacy confirmed at molecular level

Fort Lauderdale, FL-Olopatadine hydrochlo-ride ophthalmic solution (Patanol, Alcon) reduces the release of mast-cell-derived mediators and their allergic effects in the eyes of patients with allergic conjunctivitis, according to Andrea Leonardi, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares
June 29th 2025

Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

PYC to finalize registrational study for RP11 after positive FDA feedback
June 28th 2025

PYC to finalize registrational study for RP11 after positive FDA feedback

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program
June 28th 2025

Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program

(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

© 2025 MJH Life Sciences

All rights reserved.